The European Medicines Agency (EMA) has recommended revoking the marketing authorization for Amgen’s rare autoimmune disease drug, Tavneos. This decision comes after the EMA’s Committee for Medicinal Products for Human Use identified a lack of benefits that outweigh the risks associated with the drug.
Tavneos and Its Risks
Tavneos treats anti-neutrophil cytoplasmic autoantibody-associated vasculitis, a rare group of autoimmune diseases that cause inflammation in small- to medium-sized blood vessels. However, the U.S. FDA’s Center for Drug Evaluation and Research had previously proposed withdrawing approval of Tavneos due to 76 cases of drug-induced liver injury with evidence suggesting a causal link to the drug.
The EMA’s recommendation advises that no new patients should start treatment with Tavneos, while existing patients should be switched to suitable alternatives. This decision highlights the importance of continuously monitoring the safety and efficacy of drugs, especially those used to treat rare and complex conditions.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
